BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 17317825)

  • 1. Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer.
    Hou P; Liu D; Shan Y; Hu S; Studeman K; Condouris S; Wang Y; Trink A; El-Naggar AK; Tallini G; Vasko V; Xing M
    Clin Cancer Res; 2007 Feb; 13(4):1161-70. PubMed ID: 17317825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers.
    Liu Z; Hou P; Ji M; Guan H; Studeman K; Jensen K; Vasko V; El-Naggar AK; Xing M
    J Clin Endocrinol Metab; 2008 Aug; 93(8):3106-16. PubMed ID: 18492751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer.
    Xing M
    Thyroid; 2010 Jul; 20(7):697-706. PubMed ID: 20578891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/akt pathway in thyroid tumors.
    Wang Y; Hou P; Yu H; Wang W; Ji M; Zhao S; Yan S; Sun X; Liu D; Shi B; Zhu G; Condouris S; Xing M
    J Clin Endocrinol Metab; 2007 Jun; 92(6):2387-90. PubMed ID: 17426084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors.
    Hou P; Ji M; Xing M
    Cancer; 2008 Nov; 113(9):2440-7. PubMed ID: 18831514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer.
    Santarpia L; El-Naggar AK; Cote GJ; Myers JN; Sherman SI
    J Clin Endocrinol Metab; 2008 Jan; 93(1):278-84. PubMed ID: 17989125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutation of the PIK3CA gene in anaplastic thyroid cancer.
    García-Rostán G; Costa AM; Pereira-Castro I; Salvatore G; Hernandez R; Hermsem MJ; Herrero A; Fusco A; Cameselle-Teijeiro J; Santoro M
    Cancer Res; 2005 Nov; 65(22):10199-207. PubMed ID: 16288007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma.
    Santarpia L; Myers JN; Sherman SI; Trimarchi F; Clayman GL; El-Naggar AK
    Cancer; 2010 Jun; 116(12):2974-83. PubMed ID: 20564403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population.
    Abubaker J; Jehan Z; Bavi P; Sultana M; Al-Harbi S; Ibrahim M; Al-Nuaim A; Ahmed M; Amin T; Al-Fehaily M; Al-Sanea O; Al-Dayel F; Uddin S; Al-Kuraya KS
    J Clin Endocrinol Metab; 2008 Feb; 93(2):611-8. PubMed ID: 18000091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin.
    Liu D; Hou P; Liu Z; Wu G; Xing M
    Cancer Res; 2009 Sep; 69(18):7311-9. PubMed ID: 19706758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anaplastic carcinoma of the thyroid arising more often from follicular carcinoma than papillary carcinoma.
    Wang HM; Huang YW; Huang JS; Wang CH; Kok VC; Hung CM; Chen HM; Tzen CY
    Ann Surg Oncol; 2007 Oct; 14(10):3011-8. PubMed ID: 17638058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAF(K601E) mutation in a patient with a follicular thyroid carcinoma.
    Pennelli G; Vianello F; Barollo S; Pezzani R; Merante Boschin I; Pelizzo MR; Mantero F; Rugge M; Mian C
    Thyroid; 2011 Dec; 21(12):1393-6. PubMed ID: 22136270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors.
    Wu G; Mambo E; Guo Z; Hu S; Huang X; Gollin SM; Trink B; Ladenson PW; Sidransky D; Xing M
    J Clin Endocrinol Metab; 2005 Aug; 90(8):4688-93. PubMed ID: 15928251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of RASAL1 as a major tumor suppressor gene in thyroid cancer.
    Liu D; Yang C; Bojdani E; Murugan AK; Xing M
    J Natl Cancer Inst; 2013 Nov; 105(21):1617-27. PubMed ID: 24136889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activating BRAF and PIK3CA mutations cooperate to promote anaplastic thyroid carcinogenesis.
    Charles RP; Silva J; Iezza G; Phillips WA; McMahon M
    Mol Cancer Res; 2014 Jul; 12(7):979-86. PubMed ID: 24770869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The next generation of orthotopic thyroid cancer models: immunocompetent orthotopic mouse models of BRAF V600E-positive papillary and anaplastic thyroid carcinoma.
    Vanden Borre P; McFadden DG; Gunda V; Sadow PM; Varmeh S; Bernasconi M; Jacks T; Parangi S
    Thyroid; 2014 Apr; 24(4):705-14. PubMed ID: 24295207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Pathology of Anaplastic Thyroid Carcinomas: A Retrospective Study of 144 Cases.
    Bonhomme B; Godbert Y; Perot G; Al Ghuzlan A; Bardet S; Belleannée G; Crinière L; Do Cao C; Fouilloux G; Guyetant S; Kelly A; Leboulleux S; Buffet C; Leteurtre E; Michels JJ; Tissier F; Toubert ME; Wassef M; Pinard C; Hostein I; Soubeyran I
    Thyroid; 2017 May; 27(5):682-692. PubMed ID: 28351340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation.
    Oda K; Okada J; Timmerman L; Rodriguez-Viciana P; Stokoe D; Shoji K; Taketani Y; Kuramoto H; Knight ZA; Shokat KM; McCormick F
    Cancer Res; 2008 Oct; 68(19):8127-36. PubMed ID: 18829572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutational and immunohistochemical study of the PI3K/Akt pathway in papillary thyroid carcinoma in Greece.
    Sozopoulos E; Litsiou H; Voutsinas G; Mitsiades N; Anagnostakis N; Tseva T; Patsouris E; Tseleni-Balafouta S
    Endocr Pathol; 2010 Jun; 21(2):90-100. PubMed ID: 20186503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
    Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
    Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.